Every material Form 8-K Albemarle filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Albemarle Corporation disclosed that director Dean L. Seavers tendered his resignation from its Board of Directors and all committees he serves on, effective December 12, 2025. The company states the resignation is not related to any disagreement over its operations, policies, or practices, so the filing does not point to a dispute with management. For shareholders, this is a routine board change that the filing does not tie to any financial result.
Dean L. Seavers tendered his resignation on December 8, 2025.
Resignation takes effect December 12, 2025, from the board and all committees he serves on.
The company says the resignation is not related to any disagreement about operations, policies, or practices.
Albemarle reported third-quarter 2025 net sales of $1.3 billion, down 3.5% from a year earlier, mainly on lower Energy Storage pricing. The company posted a net loss of $161 million, or $1.72 per diluted share, which includes a non-cash goodwill impairment charge tied to Ketjen, but adjusted EBITDA rose 7% to $226 million and management said full-year 2025 results are now expected toward the higher end of its $9/kg lithium price scenario ranges, which matters to shareholders because it signals a stronger expected year despite the charge.
Net sales were $1.3 billion, down 3.5% from $1.35 billion in the third quarter of 2024; Energy Storage pricing fell 16% while volumes rose 8%.
Net loss attributable to Albemarle was $161 million, or $1.72 per diluted share, including a $181 million goodwill impairment charge associated with Ketjen.
Adjusted EBITDA was $226 million, up 7%; adjusted loss was $0.19 per diluted share versus $1.55 a year earlier.
Full-year 2025 outlook was enhanced toward the higher end of the $9/kg scenario ranges, capital expenditures are now expected at about $600 million, and positive free cash flow of $300 million to $400 million is expected.
Albemarle agreed to sell a controlling stake in Ketjen's refining catalyst business to KPS Capital Partners and to sell its 50% stake in the Eurecat joint venture to Axens SA. The company expects total pre-tax cash proceeds of about $660 million, and it will record a non-cash goodwill impairment charge of $181.5 million in the third quarter of 2025. Both transactions are expected to close in the first half of 2026, subject to regulatory approvals.
Albemarle expects to receive an estimated $536 million in cash from the KPS transaction and about $660 million in total pre-tax proceeds across both deals
Non-cash goodwill impairment charge of $181.5 million in Q3 2025, covering the full goodwill of the Refining Solutions reporting unit
Albemarle will keep an approximately 49% stake in Ketjen and retain the Performance Catalyst Solutions business, including the Pasadena, Texas plant
Both transactions are expected to close in the first half of 2026; either party may terminate if not closed by April 30, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Albemarle filing is on SEC EDGAR ↗. 8-K briefs of other companies →